Peptides Used Under Medical Supervision as Part of Root Cause Functional Medicine
The speaker notes that peptides and LDN are used under medical supervision within their functional medicine program, implying these are not over-the-counter or self-administered protocols. This is the only safety-adjacent statement made regarding peptide use in the video — no contraindications, side effects, or drug interactions are discussed. The speaker positions medical oversight as a key differentiator of their clinic's approach versus self-directed protocols.
Peptides Referenced as Advanced Clinical Tools Most Specialists Are Unaware Of
The speaker frames peptides (alongside LDN) as advanced tools that 'most specialists have never heard of,' positioning them as a distinguishing feature of functional medicine practice versus conventional care. The cost of LDN ($30–$90/month from compounding pharmacies) is mentioned as context for accessibility, though no peptide pricing is given. This framing serves as both a clinical observation and a marketing claim. No safety warnings or contraindications are discussed for the peptides.
Peptides Positioned as Complementary to LDN — Each Addressing Distinct Mechanisms
The speaker explicitly distinguishes the mechanisms of peptides from those of LDN, stating that 'no peptides can do what LDN does' in targeting central nervous system inflammation via microglial pathways. This implies the peptides in the stack are viewed as complementary rather than interchangeable with LDN, each filling a different mechanistic role (gut lining, NF-κB, tight junctions vs. CNS immune modulation). No dosages are specified. This framing positions the combined protocol as superior to any single agent.
Peptide Stack Combined with LDN and GLP-1 as a Multi-Modal Anti-Inflammatory Protocol
The speaker describes layering the peptide stack (BPC-157, KPV, Larazotide) on top of Low Dose Naltrexone (LDN) and micro-dosed GLP-1 medications as a potent combined anti-inflammatory protocol. The GLP-1 micro-dosing is explicitly noted as being used for anti-inflammatory purposes rather than weight loss or diabetes management. No specific peptide dosages are given, though GLP-1 escalation from 2.5 to 10 mg over 6 months is mentioned in a patient case. This is presented as the clinic's advanced multi-system approach.
Peptides Described as Turning Off Inflammation at a Genetic Level
The speaker makes a broad claim early in the video that peptides can 'turn off inflammation at a genetic level,' framing this as a distinguishing feature of the clinical tools used in their practice. This claim is most directly supported by the subsequent description of KPV's NF-κB inhibition mechanism, which operates at the level of gene transcription. No specific dosages or study citations are provided for this overarching claim. It is presented as a key differentiator from standard dietary interventions.
Peptide Stack (BPC-157 + KPV + Larazotide) for Gut and Systemic Inflammation
The speaker describes a three-peptide clinical stack combining BPC-157, KPV, and Larazotide as a coordinated approach to gut and systemic inflammation. Each peptide is said to address a distinct mechanism: BPC-157 heals the gut lining and boosts antioxidants, KPV blocks NF-κB inflammatory gene activation, and Larazotide repairs tight junctions and the zonulin pathway. No individual or combined dosages are specified. This stack is presented as a standard clinical protocol in the speaker's functional medicine clinic.
KPV Peptide Blocks NF-κB — The Master Inflammatory Switch
KPV is described as entering the cell nucleus and blocking NF-κB (NF-kappa beta), which the speaker characterizes as the master inflammatory switch that controls inflammatory gene expression. By inhibiting NF-κB, KPV is said to prevent the activation of inflammatory genes at a genetic level. No specific dosage or frequency is mentioned. This is presented as a clinical tool used in the speaker's practice.
GLP-1 Medications Do Not Repair Gut Lining Despite Systemic Anti-Inflammatory Effects
Dr. Jones asserts that while GLP-1 receptor agonists reduce inflammation systemically, they do not specifically repair a compromised gut barrier. He claims that if gut barrier integrity is not restored, inflammation will continue to recycle regardless of GLP-1 medication use — establishing the rationale for adjunct peptide therapy with KPV and BPC-157.
Gut Inflammation Reduction Improves Insulin Resistance and GLP-1 Efficacy
Dr. Jones describes a compounding downstream effect: when gut inflammation is reduced (via KPV and BPC-157), insulin resistance improves, and when insulin resistance improves, the GLP-1 medication becomes more effective. He frames persistent gut inflammation as a 'bottleneck' limiting GLP-1 drug performance.
KPV Mechanism: Direct Action on Intestinal Tight Junctions
Dr. Jones describes KPV as a targeted anti-inflammatory peptide that works directly on intestinal tight junctions — the structural points where 'leaky gut' occurs. He positions it as addressing a gap that GLP-1 medications cannot fill: while GLP-1 agonists reduce systemic inflammation, they do not specifically repair the gut barrier. No dosage specified.
Oral BPC-157 + KPV Stack for Gut Inflammation
The speaker recommends combining oral BPC-157 with KPV (alpha-MSH fragment) as one of the most effective inflammation reduction protocols seen in his clinic. The combination is said to improve the gut barrier and produce downstream anti-inflammatory effects throughout the entire body. No dosages or cycling details were provided.
Integrated autoimmune protocol: root cause + peptides + medical oversight
Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.
BPC-157, KPV, and Larazotide for gut repair and systemic inflammation in autoimmune patients
As part of a layered functional medicine protocol for autoimmune conditions, Dr. Jones recommends peptides BPC-157 ('BPC57' as spoken), KPV, and Larazotide specifically for gut repair and reducing systemic inflammation. These are positioned as advanced tools used after foundational interventions (gut health, anti-inflammatory diet, nutrient repletion) are in place. No specific dosages are provided.
KPV addresses three biological failures model (inflammation, insulin resistance, mitochondrial dysfunction)
Dr. Bachmeyer claims KPV solves his 'three biological failures' that he believes underlie every disease: (1) systemic inflammation — via melanocortin receptor activation and macrophage phenotype shifting, (2) insulin resistance — via TNF-alpha reduction improving insulin signaling (HOMA-IR decreased 35%), and (3) mitochondrial dysfunction/ATP shortage — via improved glucose uptake and removal of inflammatory mitochondrial damage. All diseases are 'the same disease with different presentations.'
KPV + TB-500 stack for comprehensive cardiovascular disease resolution
The core thesis is that KPV addresses the root cause of cardiovascular disease (chronic systemic inflammation — restoring endothelial function, resolving inflammation, stabilizing plaque) while TB-500 addresses downstream tissue damage (cardiac scarring, fibrosis, structural remodeling). Together they are positioned as a comprehensive two-pronged solution. No specific dosages or protocol timing mentioned in the available transcript.
Safety claim: cannot overdose on KPV, BPC-157, or TB-500
Dr. Bachmeyer claims that you cannot overdose and die from KPV, BPC-157, or TB-500, contrasting these with statins, NSAIDs, and prednisone which can cause fatal overdose. He argues that since the body naturally produces the parent compounds (e.g., alpha-MSH for KPV), they are inherently safer than synthetic pharmaceuticals.
KPV is immune restoration, not immunosuppression
Dr. Bachmeyer emphasizes that KPV does not suppress immune activation like NSAIDs, steroids, or corticosteroids. Instead, it restores immune regulation by repairing the immune system's natural braking mechanisms (T-regulatory cells). It is described as 'comprehensive immune optimization' rather than suppression.
KPV confers centenarian-like immune profile
Dr. Bachmeyer argues that KPV confers an immune profile similar to centenarians, who exhibit lower baseline inflammatory markers, superior inflammation resolution capacity, higher SPM levels, better endothelial function, and healthier HDL composition. The claim is that KPV enables the rapid inflammation resolution characteristic of people living past 100. Referenced context: Fuchi and Fabri in Gerontology (centenarian immune profiles).
Full EBV peptide protocol stack — TA1, KPV, SS-31, MOTS-c with supplements
The complete EBV protocol combines four peptides with nutritional support: Thymosin Alpha-1 (1 mg 2x/week, 12 weeks) for T-cell retraining, KPV (400 mcg 2x/day) for inflammatory cytokine suppression, SS-31 + MOTS-c (stacked) for mitochondrial repair. Supplements include monolaurin (titrate 500 mg to 2-3 g/day), L-lysine (2-3 g/day in 3 doses), selenium (200 mcg/day), and DGL (600 mg/day). A 2022 study (Prusty, Viruses) showed combination antiviral + immune-supportive therapy achieved 67% viral load reduction and 71% symptom improvement sustained at 12-month follow-up.
Complete HSV Peptide + Supplement Stack Protocol
Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.